耳鼻喉科Pubmed文献追踪每日 14:00 同步
← 返回全部文献
Article record

EUFOREA 2026 上下气道疾病生物制剂袖珍指南

Pocket guide Biologics in upper and lower airway diseases 2026 by EUFOREA.

指南共识鼻科IF 4.9Q1

文献信息

中文摘要

在过去十年中,靶向关键炎症通路的生物制剂治疗从根本上改变了慢性炎症性气道疾病患者的治疗格局。这些疗法目前已在全球范围内广泛获批,并越来越多地应用于常规临床实践(1)。真实世界研究证实了其在对照临床试验环境之外的有效性,并强调生物制剂是重度未控制慢性鼻窦炎伴鼻息肉(CRSwNP)、哮喘和嗜酸性慢性阻塞性肺疾病(COPD)的重大治疗进展(2-4)。生物制剂已被证明可显著改善疾病控制,并可能有助于实现新的治疗目标,包括临床缓解和完全缓解(5)。

英文摘要

Over the past decade, biologic therapies targeting key inflammatory pathways have fundamentally transformed the treatment landscape for patients with chronic inflammatory airway diseases. These therapies are now widely approved worldwide and increasingly implemented in routine clinical practice (1). Real-world studies confirm their effectiveness beyond controlled clinical trial settings and highlight biologics as a major therapeutic advance for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and eosinophilic chronic obstructive pulmonary disease (COPD) (2-4). Biologics have been shown to significantly improve disease control and potentially enable the achievement of new treatment goals, including clinical and complete remission (5).